CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Rhea-AI Summary
CapsoVision (NASDAQ: CV) will release its third quarter 2025 financial results on Thursday, November 13, 2025 after market close. The company will host a conference call and live webcast on the same day at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update.
Dial-in details: domestic (800) 715-9871, international (646) 307-1963, conference ID 2181260. The webcast link and replay registration are available on the Events page in the investor relations section of the company website. The webcast replay will remain available for one year following the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CV gained 3.83%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET
SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 2181260, or from the webcast link on the Events page in the investor relations section of the company’s website.
To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
FAQ
When will CapsoVision (CV) release Q3 2025 financial results?
What time is the CapsoVision (CV) Q3 2025 conference call and webcast?
How can investors join the CapsoVision (CV) November 13, 2025 call?
Will there be a replay of the CapsoVision (CV) Q3 2025 webcast?
Where is the CapsoVision (CV) webcast link and replay registration located?
What topics will CapsoVision (CV) cover on the November 13, 2025 call?
